Protocol Ledger

NCT05934526 · Phase III · COMPLETED

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Interventional Phase III clinical trial protocol NCT05934526 sponsored by GB002 in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-28 Enrollment: 390 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05934526
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)390 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05934526
Protocol FieldVerified Registry Value
NCT IdentifierNCT05934526
Consolidated Lead SponsorGB002
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment390 participants (ACTUAL)
Registered Start Date2023-12-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI